P1, N=30, Recruiting, Henan Cancer Hospital | Not yet recruiting --> Recruiting

To address these issues, this study engineered copper-doped ZIF-8 nanoparticles that co-deliver the hypoxia-activated prodrug TH-302 and the NQO1-targeting quinone β-lapachone, encapsulated within genetically engineered M1 macrophage membranes overexpressing CCR2 (CCR2-M)...No drug-related toxicity was observed. Thus, this rationally designed nanotherapeutic strategy significantly curtails residual tumor growth and offers a promising immunomodulatory approach to overcoming therapeutic resistance in cancer treatment after iRFA.

P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

P1, N=12, Recruiting, The Children's Hospital of Zhejiang University School of Medicine

Elevated IC₅₀ values and reduced efficacy of doxorubicin, paclitaxel, and cyclophosphamide were observed. These organoids enable efficient testing of chemotherapy responses, supporting more personalized and effective treatment selection. The scalability and adaptability of SOAR also broaden its impact beyond oncology, offering a versatile platform for high-throughput drug screening, toxicology assessments, and applications in regenerative medicine.

Mechanistically, OCA suppressed inflammation via downregulation of TLR4/MYD88/NF-κB signalling, inhibited pyroptosis through TXNIP/NLRP3/ASC/caspase-1 pathway blockade and reduced p53-mediated apoptosis by modulating BAX, BCL-2 and cleaved caspase-3 expression. This study provides the first evidence that OCA confers protection against CYC-induced thyroid injury by reducing oxidative stress, inflammation, pyroptosis and apoptosis.

Histopathological examination corroborated biochemical findings. Lacosamide demonstrates significant uro-protective efficacy through coordinated anti-inflammatory, antioxidant, and anti-apoptotic mechanisms through modulation of Notch-1/NICD/NF-κB pathway.

P2, N=20, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Dec 2025

P=N/A, N=13, Terminated, Institut Cancerologie de l'Ouest | Phase classification: P1/2 --> P=N/A

VAL-083 (30 mg/m2/day) combined with radiation therapy was generally safe and well tolerated. Adverse events aligned with previous studies. This regimen, compared to standard-of-care TMZ, showed potential benefits in terms of disease progression and overall survival. Trial registration ClinicalTrials.gov ID NCT03050736, dated: February 13, 2017.

P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026

P2, N=37, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine